ACTA NEUROPSYCHIATRICA is a distinguished journal published by Cambridge University Press, covering essential research across the fields of psychiatry and neuroscience. Since its inception in 1989, it has become a pivotal resource for researchers and clinicians, providing a platform for the latest advancements and insights in biological psychiatry. With an impressive Scopus rank of #66 out of 567 in the Psychiatry and Mental Health category, and #10 out of 51 in Biological Psychiatry, the journal is recognized for its significant contributions to the field, boasting an 88th percentile ranking in overall impact. Although it operates under a traditional access model, the journal remains committed to disseminating high-quality research that addresses critical issues in mental health. Whether you are a professional seeking the latest findings or a student aiming to deepen your knowledge, ACTA NEUROPSYCHIATRICA is an indispensable resource for cutting-edge developments that shape our understanding of the human mind.

Ideggyogyaszati Szemle-Clinical Neuroscience, an esteemed publication under the auspices of LITERATURA MEDICA, serves as a pivotal platform in the field of neurology and clinical neuroscience. Established in Hungary, this journal has been committed to advancing the understanding of neurological disorders and treatments since its inception. With its ISSN 0019-1442 and E-ISSN 2498-6208, it provides a unique local perspective alongside valuable contributions to the global discourse in neuroscience. Despite earning a Q4 quartile ranking in both Neurology and Clinical Neurology, the journal remains dedicated to publishing high-quality research that contributes to the scientific community's collective knowledge. Its coverage spans significant converged years from 1954 to 1985 and now continues through 2024, reflecting a rich historical foundation. Recognizing the importance of open access, the journal strives to enhance accessibility, albeit currently lacking a formal open-access model. Researchers, professionals, and students in the field will find in Ideggyogyaszati Szemle a resource vital for keeping abreast of emerging trends and findings in neurological science.

Middle East Current Psychiatry (MECPsych), published by SpringerNature, is a prominent open-access journal dedicated to advancing the field of psychiatry and mental health in the Middle East and beyond. Since its establishment in 2011, MECPsych has aimed to disseminate high-quality research, reviews, and reports that capture recent developments in psychiatric science, clinical practice, and public health considerations in mental well-being. With an impact factor reflective of its growing influence and classified in the Q3 quartile for Psychiatry and Mental Health, the journal offers invaluable insights backed by rigorous peer review processes. Operating under an open access model since 2019, MECPsych ensures that its articles are freely accessible to a global readership, enhancing the visibility and application of research findings. As part of its ongoing commitment to enriching understanding in the field, MECPsych also encourages submissions that explore the unique cultural, societal, and economic factors influencing mental health across the region. This approach not only supports researchers, professionals, and students in their pursuit of knowledge but also fosters a collaborative dialogue among mental health stakeholders in the Middle East and around the world.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

Schizophrenia Research and Treatment, an esteemed journal published by HINDAWI LTD, serves as a pivotal open-access platform for innovative research in the fields of Neurology and Psychiatry. With an ISSN of 2090-2085 and E-ISSN of 2090-2093, this journal has established itself as a significant resource for scholars and practitioners since its inception in 2011, consistently contributing to the understanding and treatment of schizophrenia and related mental health issues. Based in Egypt and reaching a global audience, Schizophrenia Research and Treatment is classified in the 2023 Q2 category for both Neurology (Clinical) and Psychiatry and Mental Health, reflecting its importance and relevance in these disciplines. Notably, the journal ranks in the 61st percentile for Psychiatry and Mental Health and the 58th percentile for Clinical Neurology, indicating its solid reputation among peers. By disseminating critical findings and fostering dialogue among researchers, professionals, and students, this journal plays a crucial role in advancing the treatment and management of schizophrenia, ultimately benefiting patients and healthcare systems worldwide.

SCHIZOPHRENIA BULLETIN, published by Oxford University Press, stands as a leading journal in the field of psychiatry and mental health, particularly focusing on the complexities of schizophrenia. Established in 1973, this esteemed journal covers a wide spectrum of research areas, including clinical findings, neurobiology, epidemiology, and treatment approaches, making it indispensable for researchers and practitioners alike. With its current status in the Q1 category of the psychiatry and mental health disciplines, and a remarkable Scopus rank of #34 out of 567, the journal enjoys a strong impact factor, emphasizing its contribution to advancing knowledge in mental health. Although it operates on a subscription model, the significance of the journal in disseminating groundbreaking research makes it a vital resource for those committed to improving outcomes in schizophrenia. Through its rigorous peer-review process and commitment to high-quality scientific communication, SCHIZOPHRENIA BULLETIN continues to be at the forefront of psychiatric research and discourse.

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging is a leading interdisciplinary journal published by Elsevier, focusing on the convergence of biological psychiatry, cognitive neuroscience, and advanced neuroimaging techniques. With its prestigious Q1 rankings across essential categories such as Biological Psychiatry, Cognitive Neuroscience, and Neurology (clinical), this journal is at the forefront of research that examines the complexities of mental health through innovative methodologies. Covering a broad spectrum of topics from neurobiological mechanisms to clinical applications, it aims to provide a platform for scholars and practitioners to exchange insights on mental disorders and their neurobiological underpinnings. The impact factor and Scopus rankings further underscore its importance, with rankings highlighting its position in the top percentiles of related disciplines. By fostering an open exchange of ideas and promoting cutting-edge research, this journal is an essential resource for researchers, professionals, and students dedicated to advancements in the understanding and treatment of psychiatric and neurological conditions.

Neurology Research International, published by HINDAWI LTD, is an esteemed open access journal that has been serving the neurology community since 2010. With its ISSN 2090-1852 and E-ISSN 2090-1860, this journal aims to foster knowledge dissemination and facilitate dialogue surrounding key issues in neurology and clinical neuroscience, making it a vital resource for researchers, clinicians, and students alike. It operates from the United States, with its administrative hub located in London, England. As of 2023, the journal has been positioned in the Q3 category for both neurology and clinical neurology, reflecting its commitment to advancing research within these critical fields. With a current Scopus rank of #216/400 in clinical neurology and a #113/192 in neuroscience, and a converged publication timeline from 2010 to 2024, Neurology Research International is dedicated to promoting high-quality research that addresses contemporary challenges and innovations in neurological science. By offering open access since its inception, it ensures that cutting-edge research is freely available, aligning with the global push towards accessible scientific communication.

JPAD - Journal of Prevention of Alzheimer’s Disease, published by Springer Basel AG, is a premier academic journal dedicated to advancing research in the critical field of Alzheimer’s disease prevention. Its impactful contributions to the fields of neurology, psychiatry, and mental health have led it to achieve a Q1 ranking in multiple categories, including neurology (clinical) and psychiatry and mental health. Since its inception in 2017, JPAD has become an essential platform for researchers and professionals aiming to stay at the forefront of developments in Alzheimer’s disease research, prevention strategies, and innovative therapies. The journal provides a valuable open access option for disseminating high-quality research to a global audience, enhancing its visibility and impact. With its strategic focus and rigorous peer-review process, JPAD is committed to fostering collaboration and knowledge exchange among scientists, clinicians, and practitioners, ultimately contributing to the global effort to combat Alzheimer's disease.

The Brazilian Journal of Psychiatry is a prominent peer-reviewed journal dedicated to advancing the field of psychiatry and mental health, published by the Associação Brasileira de Psiquiatria. With an impressive Q2 ranking in the Psychiatry and Mental Health category for 2023 and a Scopus rank of #130 out of 567, this journal serves as a vital resource for researchers, clinicians, and students alike. Since its transition to Open Access in 1999, it has aimed to disseminate high-quality research, innovative practices, and critical insights relevant to mental health in Brazil and beyond. The journal's focus spans various topics in psychiatry, aiming to bridge the gap between research and clinical application, making it essential reading for professionals and academicians committed to improving mental health outcomes. With a commitment to fostering scholarly discourse, the Brazilian Journal of Psychiatry not only enriches the academic landscape but also enhances the practice of psychiatry through its widespread accessibility and dedication to excellence in research.